The Administration/Communication Core (Core A) is proposed to facilitate coordination and oversight of all Program activities. This core will include a basic science director (Dr. T.-C. Wu) and a clinical research director (Dr. Edward Partridge). Dr. Wu will be responsible for coordinating basic scientific efforts and the coordination of individual projects. Dr. Partridge will oversee patient identification, enrollment, and patient monitoring in the context of the Core. This resource will also fund a Clinical Research Coordinator who will interact with the Biostatistics/Data Management Core (Core B), the Tissue/Pathology Core (Core C) and the Immunology Core (Core D), as well as with personnel from each individual project to ensure that all patient information, specimens, and results are properly collected and recorded in the computerized database. Appropriate monitoring of patient safety, adverse events, and data management and confidentiality will be provided by the data safety monitoring board, as well as the Clinical Research IVlanagement Group. The Administrative Core includes key administrative personnel and will also coordinate essential Program interactions including preparing applications and progress reports for the SPORE, all planning and evaluation activities, arranging and publicizing SPORE activities, coordinating advisory committee meetings, producing annual reports and performing analysis of budgetary matters.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA098252-09
Application #
8379250
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
9
Fiscal Year
2012
Total Cost
$282,370
Indirect Cost
$74,714
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Sinno, A K; Li, X; Thompson, R E et al. (2017) Trends and factors associated with radical cytoreductive surgery in the United States: A case for centralized care. Gynecol Oncol 145:493-499
Stewart, Katherine Ikard; Fader, Amanda N (2017) New Developments in Minimally Invasive Gynecologic Oncology Surgery. Clin Obstet Gynecol 60:330-348
Jiang, Rosie T; Wang, Joshua W; Peng, Shiwen et al. (2017) Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection. J Virol 91:
Yoo, Wonsuk; Kim, Sangmi; Huh, Warner K et al. (2017) Recent trends in racial and regional disparities in cervical cancer incidence and mortality in United States. PLoS One 12:e0172548
Moukarzel, Lea A; Angarita, Ana M; VandenBussche, Christopher et al. (2017) Preinvasive and Invasive Cervical Adenocarcinoma: Preceding Low-Risk or Negative Pap Result Increases Time to Diagnosis. J Low Genit Tract Dis 21:91-96
Huh, Warner K; Guido, Richard (2017) Transitioning from HPV 101 to HPV 202. Am J Obstet Gynecol 216:206-207
Yang, Pei-Ming; Chou, Chia-Jung; Tseng, Ssu-Hsueh et al. (2017) Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma. Oncotarget 8:46145-46162
Fader, Amanda N (2017) Minimally Invasive Techniques for Treating Gynecologic Malignancies. J Natl Compr Canc Netw 15:730-732
Mehta, Ambar; Xu, Tim; Hutfless, Susan et al. (2017) Patient, surgeon, and hospital disparities associated with benign hysterectomy approach and perioperative complications. Am J Obstet Gynecol 216:497.e1-497.e10
Yang, Andrew; Farmer, Emily; Lin, John et al. (2017) The current state of therapeutic and T cell-based vaccines against human papillomaviruses. Virus Res 231:148-165

Showing the most recent 10 out of 273 publications